COMMUNIQUÉS West-GlobeNewswire

Tilray Brands Reconfirms Strategy to Regain Nasdaq Compliance; Requests Extension to Meet Listing Requirements
14/08/2025
NEW YORK and LEAMINGTON, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle consumer packaged goods company at the forefront of the [...]
Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
14/08/2025
Exton, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical Inc. , a medical technology company focused on neurostimulation therapies for critically ill patients, today announced that the Centers for Medicare & [...]
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
14/08/2025
BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow [...]
Balt USA Responds to Patent Infringement Lawsuit Filed by Route 92 Medical
14/08/2025
IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Balt USA, LLC (“Balt”), a global leader in neurovascular medical devices, today announced it intends to vigorously defend against the allegations of patent infringement [...]
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
14/08/2025
– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell [...]
Larimar Therapeutics Reports Second Quarter 2025 Financial Results
14/08/2025
Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025 Adolescent participants from the PK run-in study and patients with FA who have not [...]
Microbix Reports Results for Q3 Fiscal 2025
14/08/2025
Revenues of $3.5 million, Weaker Gross Margin, and Net Loss MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, [...]
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
14/08/2025
VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid ® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research [...]
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
14/08/2025
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a [...]
SRx Health Solutions Announces the Cancellation of Approximately 18.8 Million Shares of its Capital Stock
14/08/2025
The Company intends to explore all available legal remedies against former officers of SRx Canada TAMPA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a [...]
Denovo Biopharma LLC to Participate in Upcoming Investor Events
14/08/2025
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced that company management will participate in upcoming August [...]
SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award
14/08/2025
Nomination recognizes SEED’s pioneering work in molecular glue development in targeted protein degradation to address high unmet medical needs Follows recent FDA IND clearance for SEED’s lead asset RBM39 degrader ST- [...]
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
14/08/2025
PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository [...]
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
14/08/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering
14/08/2025
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing [...]
Zealand Pharma Announces Financial Results for the First Half of 2025
14/08/2025
Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025 Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid [...]
Kuros Biosciences Reports First Half of 2025 Results
14/08/2025
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 [...]
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4
14/08/2025
Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Données de l’étude positive de phase 2 évaluant le rilzabrutinib pour le traitement de la maladie liée aux [...]
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
14/08/2025
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 [...]

Pages